Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Biotechnology

Healthcare
$3.75 -3.27%

-$0.20 today

Market cap
$226.76M
Beta
0.60
P/E (TTM)
-1.4
EPS (TTM)
-$4.03
52W Low $4.14High $9.94

Volume 0.95M

Average 1.29M

VNDA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Vanda Pharmaceuticals Inc.NASDAQ: VNDA

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $5.15M rose 46.2% year over year, ahead of the +24.9% change in trailing-twelve-month cost of revenue. Sequentially, it rose 34.3% from the prior quarter. Over 3 fiscal years it compounded at -18.7% a year.

Context

  • Cost of revenue amounted to 6.0% of revenue in FY2025, up 0.3 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +46.2% holds above the trailing-twelve-month pace of +24.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.15M+34.3% QoQ
Last fiscal yearDec 2025
$13.04M+15.3% YoY
LTMMar 2026
$16.42M+24.9% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+46.2%——
1 year+15.3%——
3-year CAGR-18.7%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
13.04M USD
Year-over-year change
+15.3%
4-year CAGR
-15.5%

Cost of Revenue vs competitors

How VNDA compares with its peers on the latest reported figures

  • VNDA's LTM Mar 2026 cost of revenue of $16.42M is the 7th highest of the 11 companies compared; the peer median is $28.58M.
  • Its year-over-year change of +24.9% is the 4th highest of 7, against a peer median of +24.5%.
  • Cost of revenue amounts to 7.5% of revenue for VNDA, versus a peer median of 442.3%.
VNDA Competitors Peer median
Cost of Revenue for VNDA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$77.25M -23.8%-4.7%—
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$68.13M -46.2%—186.7%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$42.41M -26.6%——
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$40.76M +72.9%——
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$40.05M ——698.0%
HUMAHumacyte, Inc.LTM Mar 2026$17.11M +85.4%+27.3%848.5%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$16.42M +24.9%-18.7%7.5%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$4M ——8.8%
IMRXImmuneering CorporationLTM Mar 2026$793.21K +354.2%+64.1%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$111K ———
SGMTSagimet Biosciences Inc.LTM Mar 2026$0 ———
Peer median (excluding VNDA) $28.58M+24.5%+27.3%442.3%

Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue268.68M254.38M192.64M198.77M216.11M
Cost of Revenue25.63M24.28M14.8M11.31M13.04M
Gross Profit243.05M230.1M177.84M187.46M203.06M
Gross Margin90.5%90.5%92.3%94.3%94.0%
Research & Development75.36M85.77M76.82M74.43M109.27M
Selling, General & Admin124.05M136.49M112.88M146.41M237.95M
Operating Expenses200.89M223.77M191.8M228.12M354.23M
Depreciation & Amortization2.84M2.73M3.01M8.13M11.92M
EBITDA45.21M14.03M9.35M(14.79M)(126.73M)
EBITDA Margin16.8%5.5%4.9%-7.4%-58.6%
Operating Income42.17M6.33M(13.95M)(40.66M)(151.17M)
Operating Margin15.7%2.5%-7.2%-20.5%-70.0%
Interest Income199K0000
Interest Expense00000
Other Income / Expenses199K4.97M20.29M17.74M12.52M
Income Before Tax42.36M11.3M6.34M(22.92M)(138.65M)
Pre-Tax Margin15.8%4.4%3.3%-11.5%-64.2%
Income Tax Expense9.21M5.03M3.83M(4.02M)81.83M
Net Income33.15M6.28M2.51M(18.9M)(220.47M)
Net Margin12.3%2.5%1.3%-9.5%-102.0%
EPS (Basic)0.600.110.04(0.32)(3.74)
EPS (Diluted)0.580.110.04(0.32)(3.74)
Weighted Avg Shares55.55M56.46M57.38M58.15M58.93M
Weighted Avg Shares (Diluted)56.92M56.98M57.56M58.15M58.93M

Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Intrinsic Alpha fair value

Locked

Current Price

$3.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.